May 2025 clinical trial highlights

In the May 2025 clinical trial highlights, we'll showcase just a few of the many trials that are enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.
Keep reading to learn more about this month’s featured trials ↓
Seeking participants with IPFALOFT-IPF Study ID: NCT06003426 Trial Phase: Phase 3 Intervention: Oral drug Sponsor: Bristol-Myers Squibb Study Contact: Clinical.Trials@bms.com, 855.907.3286 | Seeking participants with IPFDWN12088 in IPF Study ID: NCT05389215 Trial Phase: Phase 2 Intervention: Oral drug Sponsor: Daewoong Pharmaceutical Co. LTD. Study Contact: YeaRa Kwak yeara.kwak@daewoong.co.kr; +82.2.550.8010 |
Seeking participants with SSc-ILDEfzofitimod in SSc-ILD Study ID: NCT05892614 Trial Phase: Phase 2 Intervention: Intravenous injection Sponsor: aTyr Pharma, Inc. Study Contact: SScILD@cssienroll.com; 877.689.4494 | Seeking participants with fibrotic ILDPulmonary Rehabilitation and Health Coaching in Fibrotic Interstitial Lung Disease Study ID: NCT06751069 Intervention: Home-based pulmonary rehabilitation Sponsor: Mayo Clinic Study Contact: Johanna Hoult, MS hoult.johanna@mayo.edu; 507.293.1989 |
Putting a Face to the Science: Living with IPF
![]() | When Mario started feeling out of breath during a trip to South America, he thought his breathing difficulties were caused by wearing a mask in the heat. When he returned home, he went to see his doctor just to make sure. Hearing the diagnosis of idiopathic pulmonary fibrosis (IPF) was devastating. He researched the disease on the internet but only found bad news. |
Participating in IPF research helps the scientific discovery process for people like Mario. To learn more about IPF, visit the IPF webpage.
Keep reading for the latest research updates and resources ↓
RSVP for the PFF’s Clinical Trial Webinar Series in June
Trial Sponsor | Trial Title | Speaker |
Vicore Pharma AB | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis (ASPIRE) | James Nolin, PhD; Senior Clinical Science Liaison at Vicore Pharma AB |
Boehringer Ingelheim | A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis | Thomas Porter, MBA, MPH; Director, Clinical Development Lead at Boehringer Ingelheim |
Pulmonary Fibrosis Foundation | PFF Community Registry | Jessica Shore, PhD, RN; Senior Vice President, Clinical Affairs and Quality at PFF |